All In Biotech

NDA 022522 · Astrazeneca

Daliresp

Roflumilast · Oral · Phosphodiesterase 4 Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Feb 28, 2011

Approved uses

3

Original approval plus efficacy supplements

Registered trials

129

45 Phase 3, 14 recruiting

FAERS reports

6,156

4,118 serious, 958 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 12, 2020.

DALIRESP ® is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. DALIRESP is a selective phosphodiesterase 4 inhibitor indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. ( 1 , 14 ) Limitations of Use : • DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm. ( 1, 14 ) • DALIRESP 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose. ( 2, 14 ) Limitations of Use DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm. DALIRESP 250 mcg is a starting dose, for the first 4 weeks of treatment only and is not the effective (therapeutic) dose.

Mechanism: Roflumilast and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4). Roflumilast and roflumilast N-oxide inhibition of PDE4 (a major cyclic-3′,5′-adenosine monophosphate (cyclic AMP)-metabolizing enzyme in lung tissue) activity leads to accumulation of intracellular cyclic AMP. While the specific mechanism(s) by which DALIRESP exerts its therapeutic action in COPD patients is not well defined, it is thought to be related to the effects of increased intracellular cyclic AMP in lung cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • DALIRESP · ROFLUMILAST 500MCG · TABLET, ORAL · Prescription · TE AB
  • DALIRESP · ROFLUMILAST 250MCG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Roflumilast" as an intervention, any sponsor and status, largest first.

All 129 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,062
  • death743
  • chronic obstructive pulmonary disease669
  • diarrhoea539
  • pneumonia470
  • nausea461
  • weight decreased443
  • cough366
  • headache359
  • drug ineffective322
  • off label use317
  • dizziness300

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20105
201177
2012676
2013493
2014460
2015396
2016427
2017325
2018329
2019389
2020360
2021336
2022341
2023448
2024341
2025391
2026362

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Daliresp (Roflumilast)

2024 spending

$4.8M

Beneficiaries

3,123

9,113 claims

Per beneficiary

$1,539

$13.55 per unit

View as table
YearSpending
2020$189,731,323
2021$199,140,335
2022$181,447,200
2023$28,569,435
2024$4,805,759

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 147 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.